Should you Outsource your  Protein Biologics Bioprocessing?

Overview

This Q&A details important answers to questions biopharma companies must consider when deciding to develop or expand in-house production and manufacturing. We also explore the benefits of tapping into a biopharmaceutical CDMO's diverse global network of scientific experience and resources to accelerate development and manufacturing, while also reducing risk and, often, costs.

Key Takeaways

• Factors that limit scale-up for mammalian cell cultures

• key considerations for in-house vs outsourcing

• CDMO supply chain support/raw material acquisition

• Making the scale-up process more predictable